In specialty and comparator sourcing, the working assumption is that the molecule is the hard part. For restricted-access products, that's often fair. To secure an authentic, compliant supply is genuinely difficult. But there's a quieter failure point that sits downstream of procurement: whether the product that arrives can actually be administered. Fintepla (fenfluramine) oral solution…

The clock on exclusivity doesn't start when a patent expires; it starts the moment a drug is approved. For clinical operations and strategic sourcing teams, a new FDA approval triggers two immediate operational needs: calculating future generic or biosimilar entry timelines and securing the newly approved asset as a comparator for ongoing clinical programs. In…

The NCE-1 date for 𝗢𝗥𝗦𝗘𝗥𝗗𝗨® (𝗘𝗹𝗮𝗰𝗲𝘀𝘁𝗿𝗮𝗻𝘁) is January 27, 2027. While patent protection may extend to 2038, the effective Paragraph IV window opens well before the end of the decade. For generic sponsors and bioequivalence (BE) teams eyeing this market, formulation planning has already started. But here is what nobody tells you about navigating modern…

When a new therapy enters the market, it frequently shifts the baseline standard of care, subsequently altering the landscape for comparator sourcing in future clinical trials. In May 2026, the FDA approved 8 new drugs across diverse indications, ranging from metastatic breast cancer and hypertension to hospital-based anesthetic therapies and targeted antiviral treatments. Understanding these…

The FDA approvals in April 2026 introduced two important drugs that could create major opportunities. These drugs specifically would create opportunities for generic manufacturers, clinical trial sponsors, and comparator sourcing teams over the next few years. 2 approvals of Foundayo (orforglipron) and Idvynso (doravirine + islatravir) represent growing therapeutic areas with strong future market potential.…

From vaccines to cancer therapy, biologics are transforming how we treat disease. They don’t just reduce symptoms. They target the root cause. Let's dive in depth. What Are Biologics? Biologics are medicines derived from living cells or biological materials. Unlike drugs such as Aspirin or Ibuprofen, which are made using chemicals, biologics are produced inside…

The FDA approved 5 drugs in March 2026. The approved drugs span across fields like hepatology, dermatology, oncology, rare genetic disorders, and diabetes. These approvals hint at valuable opportunities for generic and biosimilar developers. For pharmaceutical companies focused on Para IV filings, aBLA pathways, and portfolio expansion, early visibility into NCE-1 timelines, data exclusivity, and…

With 1 drug approved in January 2026, we saw a great hike in the approval of drugs in the month of February. In January, the orphan drug Zycubo was approved, whereas in the month of February, 4 drugs were approved. These approvals span multiple therapeutic areas with varied significance: Dermatology Psychiatry Rare Metabolic Disorders Growth…

Understanding when a generic or biosimilar opportunity truly opens is rarely straightforward. Regulatory exclusivity and patent protection follow different timelines, and confusing them can lead to costly strategic mistakes. For companies planning generic (ANDA/Para IV) or biosimilar (aBLA) development, understanding how these timelines interact is critical. Misinterpreting them can delay development planning, affect filing strategies,…

The rare disease landscape has hit a significant milestone early in 2026. On January 12th, the FDA announced the approval of ZYCUBO (Copper Histidinate), marking a historic shift in the treatment of Menkes disease and a high-stakes entry for pharmaceutical developers. For strategic planners, this isn't just a clinical win; it’s an opportunity to navigate…